Buy Sun Pharma; target of Rs 2300: Choice Institutional Equities

What happened

Choice Institutional Equities kept a BUY rating on Sun Pharma with a target price of Rs 2300. The firm lowered its FY27E and FY28E estimates by 3.6% and 1.1% to reflect expected weakness in the US business.

Confirmed

Global impact / market context

The report ties Sun Pharma's growth to India, emerging markets, specialty launches, and biosimilars from the Organon acquisition. Biosimilars are near-copies of biologic drugs. A lower US estimate can reduce expected revenue and profit, which may affect how investors value the stock.

Analyst inference

The analyst expects India and emerging-market growth to offset near-term US challenges. Because the target price was retained despite lower estimates, the report signals that the brokerage sees the current valuation as attractive relative to its projected earnings.

Analyst inference

What to watch

1. Sun Pharma's specialty and innovative portfolio launches, plus biosimilars from the Organon acquisition, are cited as supports for sustaining growth momentum. Confirmed
2. How much US weakness actually appears matters because the brokerage cut FY27E and FY28E estimates by 3.6% and 1.1%, which can lower projected profit. Analyst inference
3. Watch whether India and emerging-market growth is strong enough to offset US pressure, as the brokerage expects, and whether that supports the Rs 2300 target. Proposed

Evidence

• Original source link unavailable